{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:45:47Z","timestamp":1764510347050},"reference-count":144,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.critrevonc.2008.01.014","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T04:40:09Z","timestamp":1206420009000},"page":"248-261","source":"Crossref","is-referenced-by-count":39,"title":["Follicular lymphomas"],"prefix":"10.1016","volume":"66","author":[{"given":"Umberto","family":"Vitolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2008.01.014_bib1","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/00000478-199208000-00011","article-title":"Incorporation of immunostaining data in anatomic pathology reports","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib2","series-title":"Malignant lymphomas: other than Hodgkin's disease: histology, cytology, ultrastructure, immunology","author":"Lennert","year":"1978"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib4","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJM197404112901501","article-title":"Nodular lymphoma\u2014evidence for origin from follicular B lymphocytes","volume":"290","author":"Jaffe","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0046-8177(91)90125-9","article-title":"Monocytoid B-cell lymphoma: a study of 36 cases","volume":"22","author":"Ngan","year":"1991","journal-title":"Hum Pathol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib7","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/1097-0142(19871201)60:11<2704::AID-CNCR2820601121>3.0.CO;2-#","article-title":"Malignant lymphomas of follicular center cell origin in man. VI. Large cleaved cell lymphoma","volume":"60","author":"Stein","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900010209","article-title":"Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method","volume":"1","author":"Mann","year":"1983","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib9","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJM198806233182502","article-title":"Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation","volume":"318","author":"Ngan","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib10","first-page":"225","article-title":"Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation","volume":"137","author":"Pezzella","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJM198701083160204","article-title":"Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer","volume":"316","author":"Yunis","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0092-8674(85)80070-2","article-title":"Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18","volume":"41","author":"Bakhshi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0092-8674(86)90362-4","article-title":"Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2\/immunoglobulin transcript resulting from the t(14;18) translocation","volume":"47","author":"Cleary","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib14","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1073\/pnas.88.16.6961","article-title":"BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death","volume":"88","author":"Hockenbery","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","article-title":"bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM199911113412007","article-title":"Cellular origin of human B-cell lymphomas","volume":"341","author":"Kuppers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib18","first-page":"2271","article-title":"Bcl-2\/JH rearrangements in benign lymphoid tissues with follicular hyperplasia","volume":"6","author":"Limpens","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2001.19.2.420","article-title":"Frequency of the Bcl-2\/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma","volume":"19","author":"Summers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib20","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib21","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2008.01.014_bib22","first-page":"123","article-title":"Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years","volume":"2","author":"Bastion","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1991.9.1.25","article-title":"Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial","volume":"9","author":"Longo","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib24","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M","article-title":"An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute","volume":"52","author":"Garvin","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/1097-0142(197908)44:2<529::AID-CNCR2820440222>3.0.CO;2-Y","article-title":"Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases","volume":"44","author":"Risdall","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib27","first-page":"651","article-title":"The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival","volume":"80","author":"O\u2019Brien","year":"1991","journal-title":"Q J Med"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib28","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","article-title":"Long-term survival after histologic transformation of low-grade follicular lymphoma","volume":"13","author":"Yuen","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib29","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib30","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.3317825","article-title":"Development of the primary antibody repertoire","volume":"238","author":"Alt","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib32","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","article-title":"The clinical significance of molecular response in indolent follicular lymphomas","volume":"91","author":"Lopez-Guillermo","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib33","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib34","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2004-06-2490","article-title":"Quantitative PCR of bone marrow BCL2\/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma","volume":"105","author":"Rambaldi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib35","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib37","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/0277-5379(91)90425-D","article-title":"Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients","volume":"27","author":"Soubeyran","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib38","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/oxfordjournals.annonc.a058044","article-title":"The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party","volume":"2","author":"Leonard","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib39","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib40","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d\u2019Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal-Celigny","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2008.01.014_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/8.suppl_1.S49","article-title":"Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III\u2013IV patients.","volume":"8","author":"Foussard","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib42","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","article-title":"Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma","volume":"12","author":"Lopez-Guillermo","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib43","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.1999.17.8.2499","article-title":"Low-grade stage III\u2013IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients\u2014a study of the groupe d\u2019Etude des lymphomes de l\u2019Adulte","volume":"17","author":"Decaudin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib44","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood.V93.7.2202","article-title":"Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features","volume":"93","author":"Rodriguez","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib45","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0959-8049(95)00635-4","article-title":"The follicular non-Hodgkin's lymphomas. II. Prognostic factors: what do they mean?","volume":"32A","author":"Denham","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib46","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1046\/j.1365-2141.2000.02084.x","article-title":"In vivo depletion of B cells using a combination of high-dose cytosine arabinoside\/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma","volume":"109","author":"Voso","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib47","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2002-02-0621","article-title":"High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"100","author":"Ladetto","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","article-title":"High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up","volume":"18","author":"Apostolidis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib49","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood.V84.4.1043.1043","article-title":"Prognostic value of chromosomal abnormalities in follicular lymphoma","volume":"84","author":"Tilly","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib50","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2006.10.5833","article-title":"Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group","volume":"25","author":"Klapper","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib51","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib52","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib53","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","article-title":"p53 mutation is associated with progression in follicular lymphomas","volume":"82","author":"Sander","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib54","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V80.3.758.758","article-title":"MYC rearrangements in histologically progressed follicular lymphomas","volume":"80","author":"Yano","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.0.CO;2-K","article-title":"Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma","volume":"22","author":"Dreyling","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib56","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood.V91.12.4677","article-title":"Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma","volume":"91","author":"Elenitoba-Johnson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib57","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V91.8.2977.2977_2977_2984","article-title":"p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas","volume":"91","author":"Pinyol","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib58","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib59","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib60","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdi269","article-title":"Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems","volume":"16","author":"Perea","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib61","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib62","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib63","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1002\/1097-0142(19950501)75:9<2361::AID-CNCR2820750928>3.0.CO;2-N","article-title":"Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma","volume":"75","author":"Besa","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-8140(95)01600-L","article-title":"Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma","volume":"36","author":"Pendlebury","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00631-1","article-title":"Is comprehensive lymphatic irradiation for low-grade non-Hodgkin's lymphoma curative therapy? Long-term experience at a single institution","volume":"38","author":"De Los Santos","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib66","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"issue":"14S","key":"10.1016\/j.critrevonc.2008.01.014_bib67","first-page":"561","article-title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone","volume":"22","author":"Petersen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib68","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib69","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/oxfordjournals.annonc.a010720","article-title":"Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center","volume":"7","author":"Soubeyran","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib70","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/1097-0142(19861015)58:8<1596::AID-CNCR2820580803>3.0.CO;2-G","article-title":"Stage I\u2013II follicular lymphoma. Treatment results for 76 patients","volume":"58","author":"McLaughlin","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib71","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0167-8140(84)80072-9","article-title":"Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975\u20131980 EORTC controlled lymphoma trial","volume":"2","author":"Carde","year":"1984","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0360-3016(80)90027-9","article-title":"Improved five year survival after combined radiotherapy\u2013chemotherapy for stage I\u2013II non-Hodgkin's lymphoma","volume":"6","author":"Monfardini","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib73","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0360-3016(99)00051-6","article-title":"The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma","volume":"44","author":"Kamath","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib74","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for Stage I\u2013II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib75","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I\u2013II indolent non-Hodgkin's lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib76","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/JCO.1993.11.2.233","article-title":"Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results","volume":"11","author":"Jacobs","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(00)00780-X","article-title":"Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University","volume":"49","author":"Murtha","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib78_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.1985.3.6.769","article-title":"Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma","volume":"3","author":"Ezdinli","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib78_2","first-page":"A59","article-title":"High-dose (HD) therapy with autologous hematopoietic support in patients with transformed follicular lymphoma (FL): a study of 27 patients (pts) from a single centre","volume":"16","author":"Foran","year":"1997","journal-title":"Proc ASCO"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib79","first-page":"836","article-title":"Prednimustine, mitoxantrone (PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group","volume":"10","author":"Unterhalt","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02841860151116286","article-title":"A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma","volume":"40","author":"Brandt","year":"2001","journal-title":"Acta Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib81","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2003.05.128","article-title":"Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B","volume":"21","author":"Peterson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib82","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.1993.11.4.644","article-title":"Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy","volume":"11","author":"Dana","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib83","first-page":"1236","article-title":"Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation","volume":"90","author":"Barosi","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib84","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1023\/A:1008347425795","article-title":"Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"10","author":"Coiffier","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib85","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.2005.03.7952","article-title":"Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma","volume":"24","author":"Hagenbeek","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib86","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","article-title":"Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma","volume":"14","author":"McLaughlin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib87","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2003.09.047","article-title":"Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501","volume":"21","author":"Velasquez","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib88","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":"Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma","volume":"22","author":"Zinzani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib89","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002371-200101000-00007","article-title":"Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma","volume":"24","author":"Allen","year":"2001","journal-title":"J Immunother"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib90","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib91","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib92","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib93","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib94","first-page":"400a","article-title":"A brief course of chemo-immunotherapy FND+rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis","volume":"102","author":"Vitolo","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib95","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","article-title":"Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib96","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib97","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib98","author":"Herold","year":"2004","journal-title":"ASH"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib99","article-title":"Rituximab added to \u00e1IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. ASH 2004","author":"Salles","year":"2004","journal-title":"ASH"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib100","first-page":"576","article-title":"Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases","volume":"9","author":"Morel","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib101","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib102","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib103","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib104","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib105","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00d74 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib106","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1023\/A:1008228709612","article-title":"Fludarabine\u2013mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma","volume":"8","author":"Zinzani","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib107","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib108","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma","volume":"12","author":"Rohatiner","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib109","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","article-title":"High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol","volume":"11","author":"Brice","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib110","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","article-title":"A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma","volume":"13","author":"Sabloff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib111","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib112","first-page":"100","article-title":"Autologous stem cell transplantation (ASCT) in 419 patients with follicular lymphoma (FL)","author":"Conde","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib113","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","article-title":"Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index","volume":"14","author":"Vose","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib114","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1200\/JCO.1999.17.1.216","article-title":"Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma","volume":"17","author":"Apostolidis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib115","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.1999.01627.x","article-title":"Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation","volume":"106","author":"Milligan","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib116","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib117","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib118","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib119","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.bmt.1704106","article-title":"Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients","volume":"32","author":"Benekli","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2141.1998.00539.x","article-title":"Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma","volume":"100","author":"Mandigers","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib121","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma","volume":"92","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib122","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib123","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","volume":"21","author":"Bierman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib124","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"Perez-Simon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib125","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib126","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib127","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib128","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib129","first-page":"595","article-title":"Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin's lymphoma (NHL)","volume":"22","author":"Emmanouilides","year":"2003","journal-title":"Proc ASCO"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib130","first-page":"574","article-title":"Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular or transformed B-cell NHL: Final results of a randomized controlled trial","volume":"23","author":"Gordon","year":"2004","journal-title":"Proc ASCO"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib131","first-page":"228b","article-title":"Zevalin\u2122 radioimmunotherapy is associated with a low infection risk","volume":"98","author":"Emmanouilides","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib132","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","article-title":"Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab","volume":"105","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib133","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib134","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/bbmt.2001.v7.pm11400952","article-title":"High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience","volume":"7","author":"Cao","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib135","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1023\/A:1008349427337","article-title":"High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre","volume":"9","author":"Foran","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib136","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.1995.13.5.1096","article-title":"Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management","volume":"13","author":"van Besien","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib137","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib138","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.1999.17.5.1558","article-title":"Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation","volume":"17","author":"Macpherson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib139","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/blood.V83.11.3279.3279","article-title":"Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines","volume":"83","author":"Hawkins","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1600-065X.1995.tb00083.x","article-title":"Idiotypic DNA vaccines against B-cell lymphoma","volume":"145","author":"Stevenson","year":"1995","journal-title":"Immunol Rev"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib141","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1749-6632.1995.tb44747.x","article-title":"A genetic approach to idiotypic vaccination for B cell lymphoma","volume":"772","author":"Stevenson","year":"1995","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib142","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.01.014_bib143","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(96)11103-X","article-title":"BCL-2 antisense therapy in patients with non-Hodgkin lymphoma","volume":"349","author":"Webb","year":"1997","journal-title":"Lancet"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842808000218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842808000218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T10:00:43Z","timestamp":1588500043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842808000218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":144,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1040842808000218"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2008.01.014","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}